ArticleGut1997
K-ras mutations in patients with early colorectal cancers.
Article in Gut, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Review
- KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.Molecular diagnosis & therapy · 2013Article
- Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Targeted therapies in colorectal cancer-an integrative view by PPPM.The EPMA journal · 2013Article
- Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations.Frontiers in oncology · 2012Article
- IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2.Cancer research · 2011Article
- MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo.Cancer gene therapy · 2010Article
- Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.Targeted oncology · 2009Article
- Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics.PloS one · 2009Article
- Ras mutation impairs epithelial barrier function to a wide range of nonelectrolytes.Molecular biology of the cell · 2005Article
- Article
- APC and K-ras gene mutation in aberrant crypt foci of human colon.World journal of gastroenterology · 2001Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPublished data are contradictory about the importance of K-ras mutations in advanced tumours and are not available for early cancers.
aimsTo establish whether specific K-ras mutations are prognostic markers in early stage colorectal adenocarcinoma.
methodsThe presence of K-ras exon 1 mutations were correlated with tumour recurrence in two groups of patients: group 1 was a consecutive series of patients with resected colorectal adenocarcinoma at low risk of recurrence; group 2 were patients referred for chemotherapy after relapse of previously resected early stage tumours. K-ras mutations were detected by direct sequencing of whole tissue samples in all patients and in some, the leading edge and centre of the tumour were also microdissected out individually and sequenced.
resultsMutations were present in 26 (26.5%) of 98 patients in group 1; 14 patients developed a recurrence, four (28.5%) of whom had a K-ras mutation. Seventy nine patients have not developed tumour recurrence, 22 (28%) of whom had a mutation (p = 0.84). K-ras mutations were present in five of 14 patients in group 2. Microdissection did not increase the number of mutations detected.
conclusionsIndividual K-ras genotypes are distributed homogeneously throughout early stage colorectal adenocarcinomas, but detection of a mutation has no apparent prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.